KRAS Mutation is an inclusion criterion in 54 clinical trials for malignant solid tumor, of which 35 are open and 19 are closed. Of the trials that contain KRAS Mutation and malignant solid tumor as inclusion criteria, 33 are phase 1 (20 open), 11 are phase 1/phase 2 (8 open), and 10 are phase 2 (7 open) [5].

KRAS Mutation is an inclusion criterion in 52 clinical trials for non-small cell lung carcinoma, of which 37 are open and 15 are closed. Of the trials that contain KRAS Mutation and non-small cell lung carcinoma as inclusion criteria, 27 are phase 1 (20 open), 7 are phase 1/phase 2 (5 open), 16 are phase 2 (10 open), and 2 are phase 3 (2 open) [5].

KRAS Mutation is an inclusion criterion in 33 clinical trials for colorectal carcinoma, of which 22 are open and 11 are closed. Of the trials that contain KRAS Mutation and colorectal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 20 are phase 1 (14 open), 7 are phase 1/phase 2 (5 open), and 5 are phase 2 (2 open) [5].

KRAS Mutation is an inclusion criterion in 12 clinical trials for acute myeloid leukemia, of which 8 are open and 4 are closed. Of the trials that contain KRAS Mutation and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 4 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

KRAS Mutation is an inclusion criterion in 12 clinical trials for melanoma, of which 9 are open and 3 are closed. Of the trials that contain KRAS Mutation and melanoma as inclusion criteria, 9 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 8 clinical trials for breast carcinoma, of which 4 are open and 4 are closed. Of the trials that contain KRAS Mutation and breast carcinoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 8 clinical trials for myelodysplastic syndromes, of which 6 are open and 2 are closed. Of the trials that contain KRAS Mutation and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

KRAS Mutation is an inclusion criterion in 8 clinical trials for pancreatic carcinoma, of which 6 are open and 2 are closed. Of the trials that contain KRAS Mutation and pancreatic carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 7 clinical trials for colorectal adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain KRAS Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [5].

KRAS Mutation is an inclusion criterion in 7 clinical trials for lung adenocarcinoma, of which 7 are open and 0 are closed. Of the trials that contain KRAS Mutation and lung adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [5].

KRAS Mutation is an inclusion criterion in 7 clinical trials for ovarian carcinoma, of which 4 are open and 3 are closed. Of the trials that contain KRAS Mutation and ovarian carcinoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 6 clinical trials for chronic myelomonocytic leukemia, of which 5 are open and 1 is closed. Of the trials that contain KRAS Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

KRAS Mutation is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 4 are open and 2 are closed. Of the trials that contain KRAS Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [5].

KRAS Mutation is an inclusion criterion in 6 clinical trials for squamous cell lung carcinoma, of which 3 are open and 3 are closed. Of the trials that contain KRAS Mutation and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 4 are phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 5 clinical trials for endometrial carcinoma, of which 5 are open and 0 are closed. Of the trials that contain KRAS Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [5].

KRAS Mutation is an inclusion criterion in 4 clinical trials for bladder carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS Mutation and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 4 clinical trials for esophageal carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and pancreatic adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and cancer as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for hepatocellular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS Mutation and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for renal cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and renal cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 2 are closed. Of the trials that contain KRAS Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for ampulla of vater carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and ampulla of vater carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for cutaneous melanoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 0 are open and 2 are closed. Of the trials that contain KRAS Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for glioblastoma, of which 0 are open and 2 are closed. Of the trials that contain KRAS Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for low grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and kidney carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant testicular neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant testicular neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal low grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and primary peritoneal low grade serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].